2024-10-18 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Analysis Report

**1. Performance vs. S&P 500 (VOO):**

Eli Lilly and Co. (LLY) has significantly outperformed the S&P 500 (VOO) with a cumulative return of 883.11%, compared to VOO's 136.93%. This translates to a difference of 746.18%, representing 92.59% of the historical range of performance difference between the two. This suggests that LLY has historically outperformed VOO significantly and is currently performing at a level close to its historical high.

**2. Recent Price Movements:**

As of today, LLY's closing price is $916.42. Here's a look at its recent price movements:

* **5-day Moving Average:** $919.98
* **20-day Moving Average:** $907.40
* **60-day Moving Average:** $897.60

The stock is currently trading slightly below its 5-day moving average, suggesting short-term bearish momentum. However, it is still above its 20-day and 60-day moving averages, indicating a long-term bullish trend.

**3. Technical Indicators:**

* **RSI:** 52.55 -  The RSI indicates that LLY is currently in neutral territory, neither overbought nor oversold.
* **PPO:** 0.27 - The PPO suggests a positive momentum in the stock price.
* **Delta_Previous_Relative_Divergence:** -0.18 - This indicates a slight decline in the recent relative performance of LLY compared to the S&P 500.
* **Expected Return:** 35.32853504374999% - This represents the potential maximum 5-year return expectation for LLY, exceeding the S&P 500.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-08 | 3.29 | 11.30 B$ |
| 2024-04-30 | 2.49 | 8.77 B$ |
| 2023-11-02 | -0.06 | 9.50 B$ |
| 2023-08-08 | 1.96 | 8.31 B$ |
| 2024-08-08 | 1.96 | 8.31 B$ |

The most recent earnings, reported on 2024-08-08, were **above analyst expectations** with an EPS of 3.29.  Revenue for the quarter was $11.30 billion, also exceeding expectations. 

Overall, Eli Lilly has demonstrated consistent revenue growth and profitability. This is fueled by strong demand for their innovative drugs, including treatments for diabetes and cancer.

**5. News and Recent Issues:**

The recent market outlook for LLY remains positive, driven by its strong earnings performance, a robust drug pipeline, and favorable market conditions.  Analysts have a "Buy" or "Strong Buy" rating on LLY, citing the company's consistent growth potential and its presence in the healthcare sector.  Some recent highlights include:

* **Strong drug pipeline:** Eli Lilly has a robust pipeline of new drugs under development, including promising treatments for Alzheimer's disease, obesity, and other chronic conditions. This pipeline has the potential to drive significant growth in the future.
* **Expansion into new markets:** The company is expanding its presence in emerging markets, which are expected to experience rapid growth in healthcare spending in the coming years.

**6. Overall Analysis:**

Eli Lilly and Co. is a strong performer with a solid track record of growth and profitability. The company is well-positioned to benefit from the growing demand for healthcare services and is expected to continue to generate significant returns for investors. The recent earnings report reinforces this positive outlook, and the stock's technical indicators point towards potential growth in the near future. 

**7. Conclusion:**

Overall, LLY appears to be a strong investment option with a compelling combination of strong earnings, a promising drug pipeline, and favorable market conditions.  While the recent short-term performance might show some minor downturns, its long-term growth potential and position in the healthcare sector suggest continued success. 
